FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ( " FDA " ) has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for patients with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials